Skip to Main Content

Paper Details

ApoA-I Infusion Therapies Following Acute Coronary Syndrome: Past, Present, and Future.
Current Atherosclerosis Reports
5
2022
-, Acute Coronary Syndrome, ApoA-1 Milano, ApoA-I, Apolipoprotein A-I, CER, CER-, CER-001, CSL111, CSL112, HDL, HDL particles, HDL-, HDL-C, LCAT, MDCO-216, apoA-1 Milano, apoA-I, apoA-I Milano, atherosclerotic, atherosclerotic plaque, cardiac events, cholesterol, cholesterol-laden macrophages, coronary, endogenous apoA-I, high-density lipoprotein cholesterol, human, human plasma, human plasma apoA-I, lecithin, lecithin-cholesterol acyltransferase, myocardial infarction, native ApoA-I, patients, phosphatidylcholine, recombinant ApoA-I Milano, recombinant wild-type human ApoA-I
Author NameAffiliation
Paul M RidkerCenter for Cardiovascular Disease Prevention, Brigham and Women's Hospital, Harvard Medical School
Peter LibbyBrigham and Women's Hospital, Harvard Medical School
  • 1 - 2

Datasets

Release 1.2